Impact of quadrivalent human papillomavirus vaccine on genital warts in an opportunistic vaccination structure

Nonavalent human papillomavirus vaccination as alternative treatment for genital warts

“…Genital warts are the most common sexually transmitted disease and have a detrimental impact on quality of life. 1 Of the more than 200 different human papillomavirus (HPV) types, the low-risk types 6 and 11 are mainly responsible for condyloma acuminata. 2,3 For the treatment of genital warts, podophyllotoxin, imiquimod, green tea extracts, cryotherapy, CO 2 laser ablation, and surgical removal are used.…”

“…With regard to the recalcitrance of genital warts, there is little evidence of reduction in infectivity when local therapies are used 4 . HPV vaccinations are a successful preventive measure used to decrease HPV infection rates and are predominantly used to prevent the development of genital warts, cervical cancer, and other anogenital cancers 1‐3,5 . Currently, there are three licensed HPV vaccines available in the United States: Gardasil® (a quadrivalent vaccine targeting HPVs 6/11/16/18), Cervarix® (a bivalent vaccine targeting serotypes 16/18) and Gardasil® 9 (a nonavalent vaccine targeting HPVs 6/11/16/18/31/33/45/52/58).…”

“…4 HPV vaccinations are a successful preventive measure used to decrease HPV infection rates and are predominantly used to prevent the development of genital warts, cervical cancer, and other anogenital cancers. [1][2][3]5 Currently, there are three licensed HPV vaccines available in the United States: Gardasil ® (a quadrivalent vaccine targeting HPVs 6/11/16/18), Cervarix ® (a bivalent vaccine targeting serotypes 16/18) and Gardasil ® 9 (a nonavalent vaccine targeting HPVs 6/11/16/18/31/33/45/52/58). Although HPV vaccination is predominantly used as a preventative strategy, a few cases have evaluated HPV vaccination as a treatment for patients with cutaneous warts.…”

Incidence of anogenital warts: epidemiological risk factors and real-life impact of human papillomavirus vaccination

“…22 An exception to the rule of herd protection in males observed in the above countries is New Zealand, where the diagnosis of AGWs declined in women eligible for vaccination but not in men. 23 The effectiveness of HPV vaccination in reducing the incidence of AGWs has also been reported in studies from Israel 24 and Spain. 25 Furthermore, a population-based cross-sectional survey 26 of 19,199 women aged 16 to 40 years, chosen randomly from the general population in the Czech Republic, revealed a reduction of 90% in the acquisition of AGWs in immunized women from the first year of the completion of the quadrivalent vaccination.…”

“…These vaccines have led to a significant decline in AGW incidence in countries that have managed to achieve high vaccination coverage rates. 16–26 HPV vaccination has also been used off-label for the treatment of recalcitrant common warts. 27 , 28 However, HPV vaccination has created considerable controversy and the vaccination rates are low in many countries.…”